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Abstract  
The personality construct known as ‘Successful Psychopathy’ has attracted the 
interests of researchers and clinicians alike. The concept suggests an individual 
who demonstrates the core traits associated with psychopathy but is able to adapt 
and function within society to prototypical or superior standards. There has yet to 
be a sound theoretical model of this construct by which to base a psychometric 
measure. This protocol presents the ethical procedure that will endeavour to create 
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The primary objective of this investigation is to develop the first 
Successful Psychopathy psychometric measure and to validate it within a 
cohort derived from the United Kingdom (UK). 
 
Background 
A Successful Psychopath refers to an individual who demonstrates 
the core traits associated with psychopathy, whilst simultaneously being 
able to adapt within society with intact or superior levels of functioning 
(Lilienfeld, 2014). It has been speculated that such individuals would be 
able to gain status and resources with minimal effort needed (Babiak & 
Hare, 2006). In addition, these individuals would likely demonstrate certain 
traits which would better allow them to adapt and function successfully 
within society, some such traits could be resilience (Dutton, 2013), a bold 
interpersonal style (Hare, 1999), as well as reduced shame, guilt, and 
remorse (Lilienfeld & Windows, 2005). Whilst some of these traits are 
shared with prototypical psychopathy, they may also be prevalent in those 
who deviate from antisocial or criminal behaviour, similarly to one of the 
original conceptualisations of psychopathy derived by Hervey Cleckley 
(1951/2016) who suggested criminal or antisocial behaviour was not a 
likely outcome of the disorder, allowing these individuals to essentially fly 
under the radar (Widom, 1977). Moreover, these individuals could be able 
to apply these traits to gaining positions of leadership (Judge & LePine, 
2007). At the time of writing, there is currently no psychometric measure 
equipped to identify and improve understanding of these individuals who 
appear to develop atypically across the psychopathy spectrum, this is partly 
due to the ongoing debate regarding the theoretical construct of Successful 
Psychopathy and lack of a measure suited to measuring these traits within 
general population samples. As such, in order to achieve our aims, we seek 
to develop and validate the first Successful Psychopathy measure and 
investigate its reliability and validity within general population samples 
with the UK. Moreover, as the construct has never been formally defined in 
this way, and psychopaths are estimated to make up around 1% of the 
general population (Hare, 1999), this study will also seek to investigate the 
relationship between the newly developed scale and existing measures of 
psychopathy, professional success, and life success, as well as theorise on 
potential prevalence of successful psychopathy, and provide a 
comprehensive understanding of a construct which is largely controversial 
and currently holds conflicting theoretical evidence which will be beneficial 
to the research community.  
 
Objectives 
1. Develop the Successful Psychopathy psychometric scale using 
Classical Test Theory (CTT) and Rasch Analysis 
2. Validate the Successful Psychopathy Scale 
3. Assess test-retest reliability of the Successful Psychopathy Scale 
The Journal of Concurrent Disorders, 2021   https://concurrentdisorders.ca/ 
 
The Journal of Concurrent Disorders, 2021 
 
3 
Duration of studies 
Through the use of the participant crowdsourcing website Prolific 
(see ‘Recruitment Methods’), enrolment and data collection of this study is 
estimated to take around 7 months to complete, due to administering the 
measure across three occasions to determine test-retest reliability. However, 
enrolment of the initial collection will remain open until the minimum 
sample (n = 400) is met, with additional data collected if necessary. The 
minimum sample size required was based on previous scale development 
research within a similar field (Caring Uncaring Emotional inventory, 
Semel, 2016) and the minimum sample required to conduct CTT. The 
duration of this study for each participant is expected to be no longer than 




This cross-sectional study will initially involve 400 participants 
completing a battery of questionnaires at a single timepoint. Demographics 
(i.e., age & sex), the newly developed Successful Psychopathy Scale (which 
will include items developed based on theoretical understanding of the 
construct, formulated from previous literature including a systematic review 
(Wallace et al., 2019) and expert ratings), and state measures of 
psychopathy, political skill, and expectancy for success. Responses to the 
Successful Psychopathy Scale only will be taken at two additional 
timepoints (3-6 months). Responses will be measured online using survey 
software Qualtrics.  
 
Study Population, Selection Criteria, and Sample Size Justification 
All participants will provide full informed consent, as indicated by 
a button press on the first and final pages of the survey. Participants will be 
males and females aged 18 years and over, of UK nationality, and fluent in 
English.  
Sample size was derived based upon minimum and optimum sample 
sizes required to undergo Classical Test Theory or Exploratory Factor 
Analysis (CTT; EFA) and Rasch Analysis (Linacre, 1994/99; Tabachnick 
& Fidell, 2013).  
 
Recruitment Methods 
Participants will be identified through the crowdsourcing website 
Prolific (prolific.co), and the study survey will be made available to all 
members who meet the required inclusion criteria. This is an automated 
process determined through member responses to a series of questions 
answered when first signing up the platform. Prolific is thought to generate 
data quality comparable to that obtained by face-to-face means (Peer et al., 
2017). Members who go on to participate in the study will be paid an 
average of £5 per hour; roughly £0.85 for this study (10 minutes). At the 
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time of writing there are 33,469 potential participants to take part in this 
study, so data collection for this purpose is feasible. 
 
Data Collection and Study Schedule  
The initial survey will consist of the Successful Psychopathy Scale, 
plus a battery of questionnaires, which will be collected at one timepoint. 
On the first two pages of the survey, participants will be presented with all 
study information and will be asked to affirm their consent. On subsequent 
pages (not accessible unless consent has been given), participants will be 
asked to answer brief demographic questions (i.e., age, sex) prior to 
completing five psychometric measures, namely the Successful 
Psychopathy Scale (in prep; Wallace et al., 2020), the 58-item Triarchic 
Psychopathy Measure (TriPM; Patrick et al., 2010), the 30-item Generalised 
Expectancy for Success Scale (GESS; Fibel & Hale, 1978), the 42-item Life 
Success Measures Scale (LSMS; Parker & Chusmir, 1992), and the Political 
Skills Inventory (PSI; Ferris et al., 2005). Each scale will be presented, 
along with completion instructions, on a separate page, and the study will 
close with a debrief page where participants will be asked to re-affirm their 
consent. Two additional timepoints will be collected for the Successful 
Psychopathy Scale at 3- and 6-month intervals. Data will be maintained for 
as long as necessary (with identifiable data destroyed after two weeks from 
each timepoint) for the purpose of transparent and open science, with the 
exception of data obtained from participants who withdraw from the study 
either during or following participation (up to a period of two weeks). In 
such cases, any associated data will be permanently deleted. 
 
Expected Outcomes 
The research team expects the Successful Psychopathy Scale to hold 
a similar theoretical structure to the initial conceptualisation of psychopathy 
as derived by Cleckley (1955/2016). Moreover, as existing literature 
suggests, it is expected that the Successful Psychopathy Scale will be 
positively associated with self-reported boldness (Persson & Lilienfeld, 
2019), meanness (Persson & Lilienfeld, 2019), political skill (Lilienfeld et 
al, 2012). Furthermore, it is theorised that successful psychopathy will be 
positively associated with an expectancy of success within professional 
domains (e.g., status and wealth) and be negatively associated with 
disinhibition and expectancy of success in personal domains (e.g., family).  
 
Ethical considerations 
Participants will provide consent and will be debriefed following the 
study. There is no expectation of any adverse outcomes or effects on 
participants as a direct result of this study. Nevertheless, the research team 
acknowledges that questions asked within this study relate to personality, 
which may lead participants to ruminate on their wellbeing. As such, 
participants will be signposted to UK-based mental health charities (e.g., 
MIND) and their healthcare providers (e.g., general practitioners) at both 
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the point of consent and the debrief. Participants are neither asked nor 
expected to disclose any subsequent correspondence with such services to 
the research team.  
 
Withdrawals 
Reasons for Withdrawal  
Potential participants identified via Prolific are under no obligation 
to take part in the study. Participants who do consent to take part can 
withdraw their consent either during the study (by closing their web browser 
or by not affirming consent at the point of debrief) or after taking part in the 
study up to two weeks prior (by e-mailing the Principal Investigator (PI) 
using the provided e-mail address with their Prolific ID, an ID associated 
with their specific data entry). No reason for this withdrawal will be asked 
or expected to be given. Participation in the study may be automatically 
terminated (via Qualtrics settings) should the participant decline to give 
consent. No adverse events will be measurable during the study due to the 
data being collected remotely and not in person. As such, no considerations 
are made for adverse events that lead to participant termination up to two 
weeks following participation. 
 
Handling of Participant Withdrawal  
As mentioned above, participants may withdraw at any time during 
the study and up to two weeks afterwards, and participants will not be asked 
to give a reason for their withdrawal. Participants who withdraw from the 
study will be replaced, and in such instances, further participants will be 
sampled to ensure the study sample does not fall under the optimal number.  
 
Premature Termination or Suspension of Study  
Although not expected, the study may be temporarily suspended or 
prematurely terminated if there is sufficient and reasonable cause to do so. 
In such instances, the PI will directly notify the research ethics committee 
that approved the study in writing, providing reason(s) for the suspension 
and/or termination of the study. Potential circumstances which might result 
in temporary suspension or premature termination include [1] unexpected, 
significant, or unacceptable risk to participants, [2] determination of futility, 
and [3] unexpected detriment to the secure maintenance and quality of data. 
The study may resume once any concerns have been addressed and satisfy 
the needs of both the research team and research ethics committee. 
 
Statistical Analysis Plan 
All analyses for this study have been determined a priori. To 
determine the construct validity of the newly developed Successful 
Psychopathy Scale, exploratory factor analyses (CTT; EFA) will be run on 
the complete data set to determine the component structure. Once a sound 
theoretical model has been found, this will then undergo Rasch Analysis. 
Rasch Analysis has been shown to overcome some of the limitations often 
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found with CTT, for example using Differential Item Functioning (DIF) to 
determine non-consistent responses across a trait and identify candidates for 
removal from a scale. Additionally, Rasch allows precise measurements of 
individuals at the extremes of a scale (Hobart & Cano, 2009) which is 
particularly relevant when assessing Successful Psychopathy where the 
research team are interested in those extreme scores.  
To determine concurrent and convergent validity of the scale 
Pearson’s correlations and linear regressions will be conducted between 
each variable.  
 
Assessment of Safety 
Although not expected, this study will follow standard definitions of 
adverse events (AEs) and report any AEs to the research ethics committee 
for up to two weeks after the final participant has taken part in the study. 
 
Adverse Events 
Defined as any unanticipated physical or mental well-being 
occurrence, regardless of its relationship to the study, such as self-reported 
stress or anxiety following participation in the study that may or may not 
require further intervention. 
 
Serious Adverse Events  
Defined as AEs that are considered serious, such as those requiring 
hospitalisation, are life-threatening, or result in death.  
In the event of any AE being acknowledged by the research team, 
the PI will assign a level of severity to the event (Mild, Moderate, Severe) 
and assess the likelihood that said AE is related to the study protocols 
(Definitely, Probably, Possibly, Unrelated). These categories are further 
delineated in Table 1. 
 
Table 1. 
Severity and relationship of adverse event to study protocol 
Label Description 
Mild Requires no or minimal intervention; not impacting the participant  
 
Moderate Moderate inconvenience to the participant; potentially interfering with day-to-day 
activities of the participant  
 
Severe Severe inconvenience to the participant that may require intervention; severely 




Definitely The relationship between the AE and the study protocol can be clearly established  
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Probably The relationship between the AE and the study protocol cannot be clearly 
established, however there is no other reason or event which could clearly explain 
the occurrence of the AE  
 
Possibly The relationship between the AE and the study protocol cannot be clearly 
established, but the definite lack of a relationship cannot be concluded  
 





The PI will be responsible to ensure the study is conducted in 
accordance with the protocol, standards of Good Clinical Practice (GCP), 
and applicable regulatory requirements as defined by the British 
Psychological Society (BPS), and that the data recorded is valid and 
appropriately stored and maintained. To this end, data collection (via 
Prolific) will be collected in three stages to ensure quality: Stage 1 being a 
short pilot of five participants to check data quality and difficulties arising 
from the usability of the questionnaire, and Stages 2 and 3 being the 
collection of male and female responses separately to ensure a good 
distribution of data across sexes. The questionnaire pack is devised in a 
manner to minimise errors (e.g., clear instructions) and uses a ‘request 
response’ function in order to remind participants to complete all sections 
of the survey should any question be missed. To comply with ethical 
standards, although this function is enabled, participants will be able to 
subsequently skip said item should they not wish to complete it. 
No external data monitor will be appointed to ensure the study 
complies with GCP or BPS standards. Data and analysis scripts will be 
made available on request.  
 
Data Handling and Record Keeping 
The collection of personal data from the participants will be limited 
to the number and type required to perform the planned analyses and in 
order to achieve the aims of the research. Data will be maintained on 
Qualtrics (survey software and secure database) until the required sample 
size has been collected, at which point the data will be exported into an 
Excel or SPSS file format (password protected), backed-up, and 
subsequently deleted from Qualtrics. Any unique identifiers collected 
within the dataset will be permanently deleted two weeks after the final 
participant completes the study, and there will be no hard copies of the data 
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generated or maintained. Fully anonymised data will be used for data 
analysis, which will be led by the PI (LW). 
 
Research Ethics Committee 
The protocol, participant-facing documents, and questionnaire pack 
will be submitted to a local research ethics committee for review, feedback, 
and approval. Approval of all documents is required before any participant 
enters into the study. Any amendment to the protocol will undergo further 
review and approval by the research ethics committee before the changes 
are implemented to the study; however, as participation is anonymous and 
participants are not requested to provide contact details, re-consent to take 
part in the study will not be possible, and as such any data obtained prior to 
amendments will only be treated in accordance with the elements and 
procedures for which consent was given. 
 
Consent Process 
After clicking on the study link and being presented with the study 
information sheet (including all information about the study, methods of 
withdrawal, information about data management, and contact details of the 
study team and signposted services), participants will then be presented 
with the consent form on the subsequent page of the online survey. To take 
part in the study, participants must affirm their consent and understanding 
of the aforementioned information via a button press; refusal to do this will 
lead the Qualtrics software to terminate their participation with a ‘thank 
you’ message. Participants will also be shown an optional consent box for 
the test-retest follow ups at 3 and 6 months, this is not mandatory and 
selecting ‘I do not consent to take part in the follow-up survey’ will allow 
them to complete the initial questionnaire with no expectation to take part 
in any of the subsequent surveys. Participants will not have to sign, date, or 
present any additional identifiable information. Following a debrief of the 
study, and in accordance with guidelines for internet mediated research 
(BPS, 2017), participants will be asked to re-affirm their consent as a means 
of mitigating against the usage of data from participants who prematurely 
exited the study and/or those who no longer wish for their data to be used 
after completing the study. 
 
Protocol Deviation 
Protocol deviations are defined as any deviation from the ethically 
approved study protocol and can be attributed to either the research team or 
study participants. However, as the nature of the study makes it improbable 
that participants could generate protocol deviations, a research team-related 
example of a protocol deviation for this study might include the use and 
storage of data in an unapproved manner. Any protocol deviation will be 
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made aware to the research team at the earliest availability and corrective 
measures will be actioned if appropriate. Causes, actions, and results of any 
protocol deviations will be signalled to the research ethics committee in 
writing at the first available opportunity. 
 
Publication and Data Sharing Policy 
It is the intention of the research team to publish any and all findings 
of this study in written (e.g., posters, journal publications, blog posts) and 
verbal (e.g., conference paper) form. The research team might also use 
findings of this study as a base for future research submissions and/or grant 
applications. At all stages, individual participant responses and associating 
identifiable information will be kept confidential, and only group-level 
analyses will be presented/published. In accordance with emerging trends 
in open science, anonymised raw data and pre-print manuscripts will be 
made openly available. 
 
Study Personnel and Roles 
Table 2 documents the members of the research team and their 




Outline of research team personnel and associated project roles 
Personnel Role Responsibilities 
Louise Wallace Principal Investigator  Responsible for all study-
related issues 
Nadja Heym Co-Investigator Study design and final review 
Oleg Medvedev Co-Investigator Data analysis, manuscript 
drafting, final review 
Alexander Sumich Co-Investigator Final review 
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